Table 1.
Descriptive statistics of study population stratified by primary cancer site (n = 1,884,469).
| 1st cancer site | Total n | Secondary sarcoma | RT |
RIS | Follow-up time, yr | Age at diagnosis, yr | Female Gender | Race |
Stage |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | No | White | Black | Othera | Local | Regional | |||||||
| Abdomen | 1403 | 4 (0.29%) | 23.1% | 76.9% | 1 (0.07%) | 8.1 | 53.1 | 52.7% | 78.2% | 13.0% | 8.8% | 68.4% | 31.6% |
| Anal | 10,606 | 3 (0.03%) | 75.1% | 24.9% | 3 (0.03%) | 8.3 | 58.7 | 62.1% | 86.8% | 9.8% | 3.4% | 63.8% | 36.2% |
| Brain | 17,617 | 2 (0.01%) | 64.4% | 35.6% | 2 (0.01%) | 7.8 | 42.6 | 43.5% | 88.2% | 5.6% | 6.2% | 100.0% | 0 |
| Breast | 693,701 | 161 (0.02%) | 47.3% | 52.8% | 126 (0.02%) | 10.2 | 58.6 | 99.4% | 83.8% | 8.8% | 7.4% | 66.2% | 33.8% |
| Cervical | 48,824 | 17 (0.03%) | 46.5% | 53.5% | 15 (0.03%) | 12.3 | 47.1 | 100.0% | 77.4% | 12.8% | 9.8% | 67.3% | 32.7% |
| Eye | 6852 | 0 | 45.0% | 55.0% | – | 9.6 | 58.6 | 44.9% | 96.7% | 1.4% | 1.9% | 91.8% | 8.2% |
| Head | 1469 | 8 (0.54%) | 33.4% | 66.6% | 3 (0.20%) | 10.3 | 55.7 | 31.9% | 85.9% | 7.5% | 6.6% | 72.4% | 27.6% |
| Larynx | 22,125 | 3 (0.01%) | 76.0% | 24.0% | 3 (0.01%) | 11.3 | 61.7 | 18.3% | 84.5% | 11.9% | 3.6% | 64.9% | 35.1% |
| Lung | 109,858 | 9 (0.01%) | 30.4% | 69.6% | 3 (0.003%) | 6.3 | 65.3 | 51.0% | 84.3% | 9.6% | 6.1% | 53.2% | 46.8% |
| Pelvis | 2109 | 10 (0.47%) | 40.5% | 59.5% | 6 (0.28%) | 9.1 | 53.3 | 46.0% | 82.1% | 12.0% | 5.9% | 73.2% | 26.8% |
| Pharynx | 9085 | 4 (0.04%) | 88.3% | 11.7% | 4 (0.04%) | 8.6 | 57.5 | 26.3% | 69.6% | 10.5% | 19.9% | 19.8% | 80.2% |
| Prostate b | 594,271 | 75 (0.01%) | 39.3% | 60.7% | 44 (0.007%) | 7.9 | 65.7 | 0 | 80.8% | 14.1% | 5.0% | – | 100.0% |
| Rectal | 77,296 | 22 (0.03%) | 42.3% | 57.7% | 14 (0.02%) | 8.8 | 61.8 | 42.5% | 82.1% | 8.4% | 9.5% | 62.8% | 37.2% |
| Salivary | 9353 | 6 (0.06%) | 52.5% | 47.5% | 4 (0.04%) | 10.6 | 55.4 | 48.4% | 82.1% | 9.1% | 8.8% | 65.1% | 34.9% |
| Testicular | 33,387 | 5 (0.01%) | 40.4% | 59.6% | 2 (0.006%) | 13.1 | 34.8 | 0 | 93.5% | 2.4% | 4.1% | 78.6% | 21.4% |
| Thorax | 1484 | 2 (0.13%) | 41.9% | 58.1% | 1 (0.07%) | 10.2 | 52.4 | 39.2% | 82.6% | 10.2% | 7.3% | 69.3% | 30.7% |
| Thyroid | 106,381 | 6 (0.01%) | 47.8% | 52.2% | 1 (0.0009%) | 10.4 | 46.5 | 77.9% | 83.0% | 6.2% | 10.9% | 65.1% | 34.9% |
| Uterine | 138,648 | 22 (0.02%) | 29.7% | 70.3% | 10 (0.007%) | 11.6 | 60.5 | 100.0% | 87.3% | 5.8% | 6.9% | 85.3% | 14.7% |
| Total | 1,884,469 | 359 (0.02%) | 43.0% | 57.0% | 242 (0.01%) | 9.4 | 60.0 | 57.3% | 83.1% | 10.1% | 6.8% | 46.2% | 53.8% |
a
Other includes American Indian/Alaskan Native, Asian/Pacific Islander.
b
Local/regional stages combined, accounting for 31.5% of total stages.
a
By Chi-squared or Fisher’s exact test, as appropriate.